Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program
Open Access
- 1 May 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (5), 1643-1646
- https://doi.org/10.1128/aac.47.5.1643-1646.2003
Abstract
The frequency of resistance to β-lactams among nosocomial isolates has been increasing due to extended-spectrum β-lactamase (ESBL)-producing enteric bacilli. Although clinical outcome data are desirable, assessment of clinical efficacy has been limited due to the lack of a statistically meaningful number of well-documented cases. Since time above the MIC ( T >MIC) is the pharmacokinetic-pharmacodynamic (PK-PD) measure that best correlates with in vivo activity of β-lactams, a stochastic model was used to predict the probability of PK-PD target attainment ranging from 30 (P30) to 70% (P70) T >MIC, for standard dosing regimens of both piperacillin-tazobactam and cefepime against Escherichia coli and Klebsiella pneumoniae ESBL phenotypes. The P70/30 T >MIC for cefepime at 2 g every 12 h against E. coli and K. pneumoniae was 0.99/1.0 and 0.96/1.0 and for a regimen of 1 g every 12 h was 0.96/1.0 and 0.93/0.99, respectively. For piperacillin-tazobactam at 3.375 g every 4 h against E. coli and K. pneumoniae , the P70/30 T >MIC was 0.77/0.96 and 0.48/0.77 and for a regimen of 3.375 g every 6 h was 0.28/0.91 and 0.16/0.69, respectively. These data suggest that the probability of achieving T >MIC target attainment rates is generally higher with cefepime than with piperacillin-tazobactam for present-day ESBL-producing strains when one uses contemporary dosing regimens.Keywords
This publication has 25 references indexed in Scilit:
- Control of an Outbreak of Infection Due to Extended‐Spectrum β‐Lactamase–ProducingEscherichia coliin a Liver Transplantation UnitClinical Infectious Diseases, 2001
- Variations in the Prevalence of Strains Expressing an Extended‐Spectrum β‐Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific RegionClinical Infectious Diseases, 2001
- Extended-Spectrum -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on OutcomesClinical Infectious Diseases, 2001
- New -Lactamases in Gram-Negative Bacteria: Diversity and Impact on the Selection of Antimicrobial TherapyClinical Infectious Diseases, 2001
- Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC BreakpointAntimicrobial Agents and Chemotherapy, 2001
- Antimicrobial resistance issues of the futureDiagnostic Microbiology and Infectious Disease, 1996
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facilityAntimicrobial Agents and Chemotherapy, 1990
- TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAEThe Lancet, 1987
- Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1985